Seeking Alpha

Medical-device firm C.R. Bard (BCR -2.5%) dips on a mixed Q3, with net profit roughly flat Y/Y...

Medical-device firm C.R. Bard (BCR -2.5%) dips on a mixed Q3, with net profit roughly flat Y/Y as sales rose less than expected. The company blames the shortfall on a weakness in its U.S. market, where sales fell roughly 1%. Sales were stronger abroad, rising about 3%. Sales in its vascular business, its largest, were down 2.7%, while its urology unit posted a 3.2% rise. The company also announced plans to acquire privately held Neomend, a developer of sprayable surgical sealants and anti-adhesion products, for $140M.

Check out Seeking Alpha’s new Earnings Center »

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs